arrow_back Civic Audit
Share share

Medication: Greater Patent Data Transparency for More Affordable Drugs

This act aims to increase transparency in drug patent information. Pharmaceutical companies will be required to share consistent data with both the patent office and the food and drug agency. This is intended to facilitate the faster introduction of more affordable generic drugs, potentially lowering healthcare costs for citizens.
Key points
Drug companies must disclose consistent patent information to both the patent office and the food and drug agency.
Failure to fully disclose data may prevent new drug approval or weaken a company's patent protection.
The goal is to streamline the market entry of generic and biosimilar drugs, potentially leading to lower medication prices for patients.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 118_HR_5429
Sponsor: Rep. Kuster, Ann M. [D-NH-2]
Process start date: 2023-09-13